Literature DB >> 6862582

Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension.

M G Myers, J de Champlain.   

Abstract

The antihypertensive effects of atenolol and hydrochlorothiazide were compared with placebo in a randomized, double-blind crossover study, with the blood pressure responses related to sympathetic nervous system activity. Twelve patients with essential hypertension were given atenolol (100 mg), hydrochlorothiazide (50 mg), and placebo as single daily doses, each for 6 weeks. Mean supine, standing, and post-exercise blood pressures (mm Hg) on atenolol (155/94, 152/95, 177/93, respectively) and hydrochlorothiazide (154/99, 150/103, 172/96) were lower (p less than 0.01) than corresponding placebo values (172/109, 166/113, 204/111) at 6 weeks. The role of the sympathetic nervous system in the antihypertensive actions of atenolol and hydrochlorothiazide was examined. The supine plasma norepinephrine on placebo was used as an index of sympathetic activity to categorize each patient's "adrenergic status." The six "hyperadrenergic" patients with high resting norepinephrine values (mean, 302 pg/ml) exhibited a greater (p = 0.05) decrease in BP (-30/-20 mm Hg) on atenolol compared with the BP fall of -9/-11 mm Hg observed in the lower norepinephrine group (mean, 211 pg/ml). Resting plasma norepinephrine values did not predict the BP fall on hydrochlorothiazide. The "adrenergic status" of each patient as measured by the plasma norepinephrine concentration tended to be relatively constant regardless of therapy or the state of activity. In this study, atenolol was an effective antihypertensive agent comparable to hydrochlorothiazide in potency. Adrenergic status tended to predict the BP response to atenolol and was a relatively constant feature of the patients in all treatment phases.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6862582     DOI: 10.1161/01.hyp.5.4.591

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

1.  Role of host β1- and β2-adrenergic receptors in a murine model of B16 melanoma: functional involvement of β3-adrenergic receptors.

Authors:  Federica Sereni; Massimo Dal Monte; Luca Filippi; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-19       Impact factor: 3.000

2.  Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol.

Authors:  R Vandongen; B Margetts; N Deklerk; L J Beilin; P Rogers
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

3.  Responses to mental stress and physical provocations before and during long term treatment of hypertensive patients with beta-adrenoceptor blockers or hydrochlorothiazide.

Authors:  K Eliasson; T Kahan; B Hylander; P Hjemdahl
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

4.  Blood pressure and catecholamines following exercise during selective beta-blockade in hypertension.

Authors:  R Vandongen; B Margetts; L J Beilin; N deKlerk; P Rogers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.

Authors:  Gavin W K Wong; Heidi N Boyda; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2016-03-10

6.  Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive.

Authors:  Joanna Burns; David A S G Mary; Alan F Mackintosh; Stephen G Ball; John P Greenwood
Journal:  Hypertension       Date:  2004-08-23       Impact factor: 10.190

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.